The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including IBM Corp. (IBM), The Goldman Sachs Group, Inc. (GS) and Thermo Fisher Scientific Inc. (TMO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.\n\nIBM’s shares have outperformed the Zacks Computer - Integrated Systems industry over the past year (+26.8% vs. +18.8%). The company reported strong second-quarter 2025 results, with adjusted earnings and revenues beating the consensus estimate. It witnessed healthy demand trends for hybrid cloud and AI solutions, with a client-focused portfolio and broad-based growth. The acquisition of Hakkoda has strengthened its data expertise and augmented its capability to support clients’ AI transformation initiatives. IBM is collaborating with SAP to tap generative AI technology within the retail industry. The collaboration is likely to facilitate higher productivity and help accelerate business transformation in consumer-packaged goods and retail firms. However, declining net sales in the Consulting segment, owing to soft demand in some end markets, are straining margins. Macroeconomic headwinds are worrisome. IBM’s acquisition spree has also escalated integration risks.\n\nShares of Goldman Sachs have outperformed the Zacks Financial - Investment Bank industry over the past year (+47.3% vs. +42.8%). The company has beaten earnings estimates in the trailing four quarters. Its second-quarter 2025 results benefited from solid growth in the Global Banking & Markets division. Goldman Sachs’ refocus on the core strengths of investment banking (IB) and trading businesses through restructuring, along with acquisitions and expansion in private equity credit, is expected to boost its global presence and diversify revenues. Post-clearing the 2025 Fed stress test, it raised dividends. However, given the current geopolitical concerns, Goldman’s high dependence on overseas revenues is worrisome. Further, the company's rising expenses due to ongoing investments in technology are concerning. Yet its decent cash levels and solid credit profile will support its capital distribution plan.\n\nThermo Fisher’s shares have declined -5.8% over the year-to-date period against the Zacks Medical Instruments industry’s decline of -7.3%. The company is braving the ongoing tough economic conditions by leveraging GenAI as part of the PPI Business System, resulting in strong financial performance. Thermo Fisher’s growth strategy has been bolstered by several recent product launches, including Krios 5 Cryo-TEM and Orbitrap MS systems, among others, in the second quarter. Strategic acquisitions like Solventum and Olink bode well. Thermo Fisher’s Bioproduction arm remains a key driver with new facilities and product lines. The Zacks analyst expect the company’s revenues to witness a 7.3% CAGR during fiscal 2025-2027. Robust solvency further instills optimism about the stock. However, a volatile macroeconomic environment can dent its operations. Currency woes and fierce competitive pressure add to the worry.\n\nOther noteworthy reports we are featuring today include Enbridge Inc. (ENB), Reddit, Inc. (RDDT) and TELUS Corp. (TU).\n\nIBM Rides on Portfolio Strength, Solid Cloud and AI Demand\nFocus on Core Business, Decent Liquidity Aid Goldman (GS)\nNew Innovations, End Market Strength Aid Thermo Fisher (TMO)\n\nReddit (RDDT) Rides on Growing User Engagement, AI Features\nPer the Zacks analyst, Reddit is benefiting from strong growth in user engagement driven by AI-powered features, including Reddit Answers.\n\nTELUS (TU) Gains from Strong Health Services Growth\nPer the Zacks analyst, TELUS is benefitting from solid momentum in the Health Service segments, along with increasing mobility and fixed customer additions.\n\nMAP 2025 Initiatives Aid RPM's Performance, Macro Woes Ail\nPer the Zacks analyst, RPM benefits from MAP 2025 initiatives and acquisitions. Also, focus on the repair and maintenance bodes well. However, currency woes and tariff pressures are concerning.\n\nHEPACO Buyout Benefits Clean Harbors (CLH), Competition High\nPer the Zacks analyst, HEPACO acquisition expanded Clean Harbors' Environmental Services segment's field services business. High competition lowers pricing power and increases operational expenses.\n\nHigh Premiums, Solid Capital Stand Aid RenaissanceRe (RNR)\nPer the Zacks analyst, its rising premiums are driven by continued rate increases and strong segmental contributions. Moreover, a robust capital position continues to be a key catalyst.\n\nSirius XM (SIRI) Benefits from Steady ARPU, Lower User Loss\nPer the Zacks analyst, Sirius XM's prospects are expected to benefit from steady ARPU and lower subscriber loss as well as improving free cash flow.\n\nAmicus (FOLD) Banks on Galafold, Overdependence a Concern\nPer the Zacks analyst, Amicus' lead drug, Galafold, has shown solid uptake since launch. The drug has shown blockbuster potential. However, overdependence on Galafold for revenues remains a concern.\n\nEnbridge (ENB) To Gain From Its Vast Transportation Network\nPer the Zacks analyst, Enbridge's extensive crude oil and gas transportation networks in North America support its low-risk business model and generate stable, fee-based revenues.\n\nStrength in Aerospace & Defense Unit Aids RBC Bearings (RBC)\nPer the Zacks analyst, RBC Bearings is witnessing solid momentum in the Aerospace & Defense unit, driven by strength in the commercial aerospace, defense aerospace, marine and helicopter markets.\n\nHigh Rates, Loan Growth Likely to Aid Zions' (ZION) Top Line\nPer the Zacks analyst, robust loans, a solid balance sheet and relatively higher rates will support Zions top-line growth. Its capital distribution plans seem sustainable, given the earnings strength.\n\nLabor Shortage, Rising U.S. Tariffs May Hurt Embraer (ERJ)\nPer the Zacks analyst, a shortage of skilled labor may cause Embraer to miss its delivery schedule for certain products. Also, rising U.S. tariffs on imported goods pose a threat to the stock.\n\nNOV Inc. (NOV) Struggles with Aggressive Competitor Pricing\nThe Zacks analyst believes that NOV faces escalating pricing pressures and tariff challenges, threatening margins as competitors aggressively discount to regain market share amid a slowdown.\n\nHain Celestial (HAIN) Organic Sales Fall on Volume, Price\nPer the Zacks analyst, Hain Celestial's organic sales fell 5% YoY in Q3, with a 3-point drop from volume/mix and a 2-point decline from price pressures.\n\nThis article originally published on Zacks Investment Research (zacks.com).

Top Stock Reports for IBM, Goldman Sachs & Thermo Fisher

The Zacks Research Daily highlights recent performance and strategic developments for several major companies, including IBM, Goldman Sachs, and Thermo Fisher Scientific. IBM outperformed in the computer-integrated systems sector due to strong second-quarter 2025 results, driven by demand for hybrid cloud and AI solutions, and its acquisition of Hakkoda, which enhanced its data capabilities. IBM is also collaborating with SAP on generative AI for retail. However, declining consulting segment sales and integration risks from its acquisition spree are concerns. Goldman Sachs outperformed the financial sector with strong earnings and growth in global banking and markets, supported by restructuring and private equity expansion, though its reliance on overseas revenues and rising tech expenses are noted. Thermo Fisher showed resilience despite a year-to-date decline, leveraging GenAI in its PPI system and launching new products like Krios 5 Cryo-TEM and Orbitrap MS systems, with strategic acquisitions of Solventum and Olink. The article also covers reports on Reddit, TELUS, RPM, Clean Harbors, RenaissanceRe, Sirius XM, Amicus, Enbridge, RBC Bearings, Zions, Embraer, NOV, and Hain Celestial, each with specific performance drivers and risks.